gurufocus.com · 30 jun

Eli Lilly Hands China Sales Rights for Verzenio to Innovent

Eli Lilly (LLY, Financials) is turning to Innovent Biologics to handle sales of Verzenio in mainland China. The breast cancer drug has been available there sinc

proactiveinvestors.com · 30 jun

Merck, AbbVie probed by US lawmakers over China clinical trials: report

A bipartisan group of United States lawmakers has opened national security investigations into whether five major pharmaceutical companies, including Merck...

gurufocus.com · 30 jun

Eli Lilly Expands China Cancer Reach

Eli Lilly (LLY) is expanding its China oncology reach through a new commercialization agreement with Innovent Biologics for Verzenios.Under the deal, Innovent w

fool.com · 30 jun

Ranking Wall Street's Trillion-Dollar Stocks From Most to Least Attractive, Based on Future Cash Flow

Among Nvidia, Apple, Alphabet, Microsoft, Amazon, Taiwan Semi, SpaceX, Broadcom, Tesla, Meta, Micron, Eli Lilly, and Berkshire Hathaway, there are a handful of bargains and pretenders.

seekingalpha.com · 30 jun

Forget Weight Loss: Eli Lilly's Real Upside Is As An AI Compounder

Eli Lilly is leveraging its exceptional cash flow to build an AI-native drug discovery and manufacturing platform, transforming its equity narrative beyond weight loss drugs. LLY's financial momentum is extraordinary, with 2026 revenue guidance of $82–85 billion and non-GAAP EPS of $35.50–37.00, driven by Mounjaro and Zepbound. I view Lilly as an emerging AI company, with proprietary data, AI compute infrastructure, and manufacturing scale creating a compounding R&D ecosystem and operational leverage.

fool.com · 30 jun

5 Reasons Eli Lilly Is a Better Stock to Buy Right Now Than SpaceX

Investors rushed to get in on SpaceX's IPO -- and benefit from the company's innovation and growth. Eli Lilly's strength in the high-growth weight loss drug market has supercharged revenue.

reuters.com · 30 jun

China's Innovent Biologics gains commercialization rights for Eli Lilly breast cancer drug

Innovent Biologics ​has entered ‌into an agreement that ​grants ​it sole commercialization ⁠rights for ​Eli Lilly's ​breast cancer drug Verzenios in ​mainland ​China, the Chinese drugmaker ‌said ⁠Tuesday.

prnewswire.com · 30 jun

Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China

SAN FRANCISCO and SUZHOU, China, June 30, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, and Eli Lilly and Company (NYSE: LLY) today jointly announced that they have entered into a distribution and promotion agreement regarding Lilly's CDK4 & 6 inhibitor Verzenios® (abemaciclib) in mainland China: Innovent will be responsible for the importation, marketing, distribution and promotion of Verzenios® (abemaciclib) in mainland China; Lilly will continue to be responsible for manufacturing, supply, and development for the product. Verzenios® (abemaciclib), developed by Lilly, is a CDK4 & 6 inhibitor that has been approved in China for multiple indications, including: (1) Early Breast Cancer: in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence.